HK1212236A1 - Target peptides for colorectal cancer therapy and diagnostics - Google Patents
Target peptides for colorectal cancer therapy and diagnosticsInfo
- Publication number
- HK1212236A1 HK1212236A1 HK16100312.3A HK16100312A HK1212236A1 HK 1212236 A1 HK1212236 A1 HK 1212236A1 HK 16100312 A HK16100312 A HK 16100312A HK 1212236 A1 HK1212236 A1 HK 1212236A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diagnostics
- colorectal cancer
- cancer therapy
- target peptides
- peptides
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001181—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697274P | 2012-09-05 | 2012-09-05 | |
US201261712807P | 2012-10-12 | 2012-10-12 | |
US201261736466P | 2012-12-12 | 2012-12-12 | |
PCT/US2013/058255 WO2014039675A2 (fr) | 2012-09-05 | 2013-09-05 | Peptides cibles pour la thérapie et les diagnostics du cancer colorectal |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1212236A1 true HK1212236A1 (en) | 2016-06-10 |
Family
ID=50237760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100312.3A HK1212236A1 (en) | 2012-09-05 | 2016-01-12 | Target peptides for colorectal cancer therapy and diagnostics |
Country Status (6)
Country | Link |
---|---|
US (2) | US10682399B2 (fr) |
EP (2) | EP2892544A4 (fr) |
AU (4) | AU2013312529A1 (fr) |
CA (1) | CA2883673A1 (fr) |
HK (1) | HK1212236A1 (fr) |
WO (1) | WO2014039675A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10640535B2 (en) | 2012-05-25 | 2020-05-05 | Agenus Inc. | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies |
CA2883569A1 (fr) * | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Peptides cibles pour l'immunotherapie et le diagnostic |
US10682399B2 (en) | 2012-09-05 | 2020-06-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
EP3137100B1 (fr) | 2014-04-15 | 2023-12-20 | University Of Virginia Patent Foundation | Récepteurs des lymphocytes t isolés et leurs procédés d'utilisation |
DK3200818T3 (da) * | 2014-10-02 | 2022-08-22 | Us Health | Fremgangsmåder til isolering af t-cellereceptorer med antigen specificitet over for en cancer-specifik mutation |
GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
HUE056607T2 (hu) | 2014-12-23 | 2022-02-28 | Immatics Biotechnologies Gmbh | Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra |
EP3294324A1 (fr) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccins pour le traitement et la prévention du cancer |
EP3452085A4 (fr) * | 2016-05-05 | 2020-04-01 | University Of Virginia Patent Foundation | Peptides cibles pour le traitement et le diagnostic du cancer |
CN111148996A (zh) * | 2017-07-28 | 2020-05-12 | 百时美施贵宝公司 | 用于检查点抑制剂的预测性外周血生物标志物 |
EP3784688A2 (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc. | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361539A (en) | 1980-05-05 | 1982-11-30 | Instrumentation Laboratory Inc. | Analysis system |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
GB9325182D0 (en) | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
EP0756604A1 (fr) | 1994-04-22 | 1997-02-05 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Antigenes du melanome |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
EP1978033A3 (fr) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Anticorps humains dérivés à partir de xénosouris immunisée |
WO1996034096A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
JP2002515243A (ja) | 1998-05-19 | 2002-05-28 | アヴィデックス リミテッド | 多価t細胞受容体複合体 |
US6309863B1 (en) | 1999-01-25 | 2001-10-30 | Brookhaven Science Associates | Methods for generating phosphorylation site-specific immunological reagents |
US7244827B2 (en) | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
AU5047800A (en) | 1999-05-28 | 2000-12-18 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
US7166573B1 (en) | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US6054927A (en) | 1999-09-13 | 2000-04-25 | Eaton Corporation | Apparatus and method for sensing an object within a monitored zone |
US7172761B2 (en) | 2001-11-07 | 2007-02-06 | Duke University | Polyvalent immunogen |
US7449548B2 (en) * | 2001-12-07 | 2008-11-11 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer |
US20060251666A1 (en) | 2002-08-30 | 2006-11-09 | Tetsuya Nakatsura | Cancer antigens and utilization thereof |
US8784821B1 (en) | 2003-05-31 | 2014-07-22 | Amgen Research (Munich) Gmbh | Human-anti-human cd3 binding molecules |
US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20050277161A1 (en) | 2004-06-09 | 2005-12-15 | Engelhard Victor H | Phosphopeptide antigens associated with MHC molecules |
CA2571957A1 (fr) | 2004-07-01 | 2006-01-12 | Waratah Pharmaceuticals, Inc. | Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete |
WO2006099448A2 (fr) | 2005-03-14 | 2006-09-21 | University Of Iowa Research Foundation | Production acceleree des lymphocytes t memoire cd8+ apres vaccination avec les cellules dendritiques |
GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
JP5079697B2 (ja) | 2005-08-05 | 2012-11-21 | ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー | 抗原特異的t細胞の生成方法 |
US20090298093A1 (en) | 2006-04-27 | 2009-12-03 | Roberto Polakiewicz | Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways |
US7884180B2 (en) | 2006-09-18 | 2011-02-08 | Compugen Ltd | Peptides which bind to G protein-coupled receptors |
US7851230B2 (en) | 2008-04-14 | 2010-12-14 | Chang Gung Memorial Hospital | Stress-induced phosphoprotein 1 as a biomarker for the detection of human ovarian cancers and endometriosis |
WO2009134883A1 (fr) | 2008-04-29 | 2009-11-05 | Cornell University | Substances et compositions pour améliorer la réparation de l'adn et procédés d'utilisation |
WO2010037395A2 (fr) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
US9279011B2 (en) | 2009-05-05 | 2016-03-08 | The Johns Hopkins University | Phosphopeptides as melanoma vaccines |
GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
US20110059463A1 (en) | 2009-07-09 | 2011-03-10 | Cell Signaling Technology, Inc. | Serine and Threonine Phosphorylation Sites |
KR101400415B1 (ko) * | 2009-12-21 | 2014-05-28 | 한국기술교육대학교 산학협력단 | 네트워크 기반 서비스 플로우 바인딩 방법 |
US20120021432A1 (en) | 2010-04-16 | 2012-01-26 | Arqule, Inc. | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same |
KR102447139B1 (ko) | 2010-05-14 | 2022-09-23 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
WO2011149909A2 (fr) * | 2010-05-24 | 2011-12-01 | Hunt Donald F | Phosphopeptides du cmh de classe i pour l'immunothérapie et le diagnostic du cancer |
CN103097407A (zh) | 2010-07-28 | 2013-05-08 | 英美偌科有限公司 | T细胞受体 |
DE102010064168A1 (de) * | 2010-12-27 | 2012-06-28 | Infineon Technologies Ag | Verfahren zur Ansteuerung der Schalttransistoren eines Gleichrichters |
US10640535B2 (en) | 2012-05-25 | 2020-05-05 | Agenus Inc. | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies |
CA2883569A1 (fr) | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Peptides cibles pour l'immunotherapie et le diagnostic |
US10682399B2 (en) | 2012-09-05 | 2020-06-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
US20160000893A1 (en) | 2012-12-13 | 2016-01-07 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
MA45352A (fr) | 2015-08-07 | 2018-06-13 | Univ Birmingham | Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer |
EP3452085A4 (fr) | 2016-05-05 | 2020-04-01 | University Of Virginia Patent Foundation | Peptides cibles pour le traitement et le diagnostic du cancer |
-
2013
- 2013-09-05 US US14/425,946 patent/US10682399B2/en active Active
- 2013-09-05 EP EP13835570.6A patent/EP2892544A4/fr not_active Withdrawn
- 2013-09-05 EP EP22176469.9A patent/EP4088737A3/fr not_active Withdrawn
- 2013-09-05 AU AU2013312529A patent/AU2013312529A1/en not_active Abandoned
- 2013-09-05 CA CA2883673A patent/CA2883673A1/fr active Pending
- 2013-09-05 WO PCT/US2013/058255 patent/WO2014039675A2/fr active Application Filing
-
2016
- 2016-01-12 HK HK16100312.3A patent/HK1212236A1/xx unknown
-
2018
- 2018-05-21 AU AU2018203542A patent/AU2018203542A1/en not_active Abandoned
-
2020
- 2020-03-25 AU AU2020202110A patent/AU2020202110A1/en not_active Abandoned
- 2020-06-15 US US16/901,277 patent/US20210154279A1/en not_active Abandoned
-
2022
- 2022-06-21 AU AU2022204339A patent/AU2022204339A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2014039675A3 (fr) | 2015-05-14 |
CA2883673A1 (fr) | 2014-03-13 |
US20150328297A1 (en) | 2015-11-19 |
EP2892544A4 (fr) | 2016-11-02 |
AU2022204339A1 (en) | 2022-07-14 |
EP4088737A2 (fr) | 2022-11-16 |
US20210154279A1 (en) | 2021-05-27 |
US10682399B2 (en) | 2020-06-16 |
AU2013312529A1 (en) | 2015-04-16 |
WO2014039675A2 (fr) | 2014-03-13 |
AU2020202110A1 (en) | 2020-04-16 |
EP4088737A3 (fr) | 2023-02-08 |
AU2018203542A1 (en) | 2018-06-07 |
EP2892544A2 (fr) | 2015-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212236A1 (en) | Target peptides for colorectal cancer therapy and diagnostics | |
HK1216153A1 (zh) | 用於卵巢癌治療和診斷的靶向肽 | |
HK1212237A1 (en) | Target peptides for immunotherapy and diagnostics | |
GB201322725D0 (en) | Cancer therapy | |
EP2807180A4 (fr) | Agents peptidiques utilisés en thérapie anticancéreuse | |
HK1220900A1 (zh) | 癌症的治療 | |
IL238178A0 (en) | Systems and methods for the analysis of tumor clonality | |
PL2994148T3 (pl) | Terapia nowotworowa | |
EP2961412A4 (fr) | Cancérothérapie | |
SG11201502584XA (en) | Peptides and methods for treating cancer | |
EP2934500A4 (fr) | Polythérapie pour le traitement du cancer | |
HK1218939A1 (zh) | 用於非小細胞肺癌療法的藥物選擇 | |
GB201211714D0 (en) | Chelmsford colorectal cancer survillance system | |
IL239231A0 (en) | Combined cancer treatment | |
GB201317213D0 (en) | Cancer Therapy | |
GB201222791D0 (en) | Therapeutic and diagnostic target | |
GB201205010D0 (en) | Therapeutic and diagnostic target | |
GB201204923D0 (en) | Therapeutic and diagnostic target | |
GB201204764D0 (en) | Therapeutic and diagnostic target | |
GB201204754D0 (en) | Therapeutic and diagnostic target | |
GB201204744D0 (en) | Therapeutic and diagnostic target | |
GB201204658D0 (en) | Therapeutic and diagnostic target | |
GB201204567D0 (en) | Therapeutic and diagnostic target | |
GB201204578D0 (en) | Therapeutic and diagnostic target | |
GB201204561D0 (en) | Therapeutic and diagnostic target |